In UK Norton Rose Fulbright, advised on the matter.
Clifford Chance advised Polpharma SA Pharmaceutical Works with a team including Andrzej Stosio (Picture – Finance).
Norton Rose Fulbright advised BNP Paribas Bank Polska S.A., European Bank for Reconstruction and Development, Powszechna Kasa Oszczędności Bank Polski S.A., Santander Bank Polska S.A. with a team including
The transaction involved a term and revolving facility agreement in the aggregate amount of up to PLN 800 million. The financing consortium consisted of the following banks: BNP Paribas Bank Polska S.A., European Bank for Reconstruction and Development, Santander Bank Polska S.A. and PKO Bank Polski S.A. The loan will contribute to long-term development of Polpharma including R&D projects and “Go Green” transformation aimed at minimizing the environmental and climate impact of the company’s operations.
The financing provided by a consortium of banks will be made available for general corporate and working capital purposes and in order to refinance the group’s existing bank debt.
Polpharma is a leading player on the Polish pharmaceutical market and one of the major drug manufacturers in the region of Central and Eastern Europe, Central Asia and the Caucasus.
The Clifford Chance’s team advising on the financings consisted of: Andrzej Stosio (Picture – Partner, Co-head of the Warsaw Banking and Finance Department), Anna Miernik (Senior Associate) and Natalia Karasiewicz (Associate).
Norton Rose Fulbright team included Partners Grzegorz Dyczkowski and James Dunnett, Counsel Marta Kawecka, and Associate Karolina Majcher.
Involved fees earner: Natalia Karasiewicz – Clifford Chance; Anna Miernik – Clifford Chance; Andrzej Stosio – Clifford Chance; James Dunnett – Norton Rose Fulbright; Grzegorz Dyczkowski – Norton Rose Fulbright; Marta Kawecka – Norton Rose Fulbright; Karolina Majcher – Norton Rose Fulbright;